Direct quantitation of growth hormone binding protein in human serum by a ligand immunofunctional assay: comparison with immunoprecipitation and chromatographic methods.

Current methods for measuring GH-binding protein (GHBP) are laborious, require separation of GHBP complex, and may be affected by endogenous GH content of the sample. Such methods estimate binding activity and GHBP concentration can only be obtained by Scatchard analysis. We have developed and validated a 2-site immunofunctional assay for the direct quantitation of GHBP in human serum employing a capture monoclonal antibody against GHBP and a polyclonal antibody against hGH. Results were compared with binding activity data and Scatchard-derived capacity estimates obtained by immunoprecipitation and gel chromatography procedures. Serum samples were obtained from 21 subjects with GH deficiency, 24 patients with acromegaly, and 56 normal subjects; 12 of whom were postmenopausal women who were studied before and during oral estrogen treatment. Using the immunofunctional assay, serum GHBP concentrations in normal subjects ranged from 0.14-3.28 nmol/L, was positively related to body mass index (BMI, P = 0.0004) and negatively related to age (P = 0.015). Women had significantly higher levels (0.99 +/- 0.12 vs. 0.63 +/- 0.09 nmol/L; P = 0.0191) than age and BMI-matched men. GHBP levels were not different between normal, acromegalic, or GH-deficient subjects. Oral estrogen therapy in postmenopausal women increased serum GHBP concentrations up to 5-fold. There was a significant nonlinear relationship between the immunofunctional assay measurements and binding activity by either immunoprecipitation (r = 0.84) or chromatographic (r = 0.73) methods; increase in GHBP concentrations was not reflected in proportionate increase in both activity assays. Estrogen-induced changes in circulating GHBP levels were greatest with the immunofunctional assay followed by Scatchard-derived values from immunoprecipitation and chromatographic methods. We conclude that ligand immunofunctional assay measurements of GHBP are higher but show good agreement with binding activity or Scatchard derived estimates from immunoprecipitation and chromatographic methods. This assay provides a direct and practical tool for rapid, accurate and sensitive estimation of GHBP concentration in serum.

[1]  M. Waters,et al.  Different modes of growth hormone (GH) administration do not change GH binding protein activity in man , 1993, Clinical endocrinology.

[2]  M. Waters,et al.  Regulation of growth hormone binding protein in man: comparison of gel chromatography and immunoprecipitation methods. , 1993, The Journal of clinical endocrinology and metabolism.

[3]  M. Blankenstein,et al.  High affinity growth hormone binding protein in plasma of patients with acromegaly and the effect of octreotide treatment , 1992, Clinical endocrinology.

[4]  Z. Hochberg,et al.  The distal axis of growth hormone (GH) in nutritional disorders: GH-binding protein, insulin-like growth factor-I (IGF-I), and IGF-I receptors in obesity and anorexia nervosa. , 1992, Metabolism: clinical and experimental.

[5]  B. Glaser,et al.  Growth-hormone-binding protein in patients with acromegaly. , 1992, Hormone research.

[6]  A. Rowland,et al.  Ligand-mediated immunofunctional assay for quantitation of growth hormone-binding protein in human blood. , 1991, The Journal of clinical endocrinology and metabolism.

[7]  H. Imura,et al.  Effects of sex and age on serum GH binding protein levels in normal adults , 1991, Clinical endocrinology.

[8]  K. Ho,et al.  Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. , 1991, The Journal of clinical endocrinology and metabolism.

[9]  W. Daughaday,et al.  Growth hormone-binding protein: II. Studies in pygmies and normal statured subjects. , 1990, The Journal of clinical endocrinology and metabolism.

[10]  M. Waters,et al.  Regulation of growth hormone (GH) bioactivity by a recombinant human GH-binding protein. , 1990, Endocrinology.

[11]  Z. Hochberg,et al.  A new and convenient assay of growth hormone-binding protein activity in human serum. , 1990, The Journal of clinical endocrinology and metabolism.

[12]  M. Waters,et al.  Characterization of the growth hormone-binding protein of human serum using a panel of monoclonal antibodies. , 1989, The Journal of endocrinology.

[13]  M. Shaw,et al.  Regulation of plasma growth hormone-binding proteins in health and disease. , 1989, Metabolism: clinical and experimental.

[14]  R. O. Day,et al.  THE PHARMACOKINETICS, SAFETY AND ENDOCRINE EFFECTS OF AUTHENTIC BIOSYNTHETIC HUMAN GROWTH HORMONE IN NORMAL SUBJECTS , 1989, Clinical endocrinology.

[15]  B. Andrews,et al.  The ontogeny of serum GH binding protein in man: a possible indicator of hepatic GH receptor development. , 1987, The Journal of clinical endocrinology and metabolism.

[16]  A C Herington,et al.  Identification and characterization of specific binding proteins for growth hormone in normal human sera. , 1986, The Journal of clinical investigation.

[17]  M. Stolar,et al.  A specific growth hormone-binding protein in human plasma: initial characterization. , 1986, The Journal of clinical endocrinology and metabolism.